Smooth muscle cell (SMC) proliferation and migration are key processes that occur in the pathogenesis of atherosclerosis and post-angioplasty restenosis. In the present study, we designed locked nucleic acid (LNA)-modi®ed DNAzymes targeting a speci®c region spanning the translational start site of human EGR-1, an immediate-early gene, wherein two of the nucleotides in each of the 9+9 hybridizing arms of the DNAzyme were substituted with LNA monomers. In vitro cleavage experiments revealed that the LNA-modi®ed DNAzyme (LzF4) cleaved a 32 P-labelled 388 nt EGR-1 transcript with greater ef®cacy than its native unmodi®ed phosphodiester counterpart, DzF. The scrambled versions of these molecules, LzF4SCR and DzFSCR, did not display any ability to cleave the transcript. Western blot analysis revealed that both active molecules abrogated serum-inducible EGR-1 protein expression in primary human aortic SMCs and inhibited serum-inducible SMC proliferation in a dose-dependent and non-toxic manner. SMC proliferation was inhibited by >50% with LzF4 at concentrations as low as 20 nM, whereas inhibition by DzF at this concentration was not evident. Finally, LzF4 and DzF inhibited SMC regrowth from the wound edge after mechanical injury in vitro. In contrast, neither DzFSCR nor LzF4SCR had any in¯uence on EGR-1 protein expression, SMC proliferation or regrowth. These ®ndings provide the ®rst functional demonstration of LNA-modi®ed DNAzyme ef®cacy in a biological setting of any kind. These studies also demonstrate that LNA modi®cation increases DNAzyme potency without necessarily compromising speci®city.
INTRODUCTION
Antisense oligonucleotide strategies have been used to silence genes that play key roles in the progression of a varied range of disease models through their ability to bind target sequences by Watson±Crick base pairing (1, 2) . Phosphorothioate (PS) modi®cations have been employed in the backbones of normally phosphodiester-linked oligonucleotides to increase resistance against nucleolytic degradation (3) . However, the introduction of PS linkages may result in non-speci®c interactions with other proteins causing non-speci®c phenotypic effects (4, 5) .
A new class of DNA-based gene-targeting agent has been developed, through an in vitro selection technique (6) , which binds RNA and cleaves between an unpaired purine and a paired pyrimidine. These agents, termed DNAzymes, display low toxicity and need not rely on RNase H for destruction of mRNA, unlike classic antisense oligonucleotides. One of the most attractive features of DNAzymes is their ability to turn over, whereby a given DNAzyme molecule cleaves multiple target transcripts with reasonable ef®cacy. Modi®cations to DNAzymes, such as phosphorothioate backbones or the addition of a 3¢±3¢-inverted T have been used to prolong the stability of these molecules (7±9). DNAzymes are useful as molecular tools to investigate the functions of the targeted gene in a biological system, or potentially useful as therapeutic tools in different disease states (10) .
Recently a new type of ribonucleotide analogue, known as locked nucleic acids (LNAs), have been introduced into both antisense oligonucleotides (11, 12) and DNAzymes (9, 13) . LNA bases contain a 2¢-O, 4-C-methylene bridge that lock in a C3¢-endo conformation (11, 12) . Constraint on the ribose ring increases binding af®nity for complementary sequences and increases the melting temperature of the LNA-incorporated oligonucleotide (14, 15) . Recent studies have demonstrated that LNA-incorporated oligonucleotides can be transiently transfected into cells using cationic lipid-based transfection reagents (16, 17) . However, there are presently no studies that have evaluated the biological ef®ciency of LNA-modi®ed DNAzymes.
Smooth muscle cell (SMC) proliferation and migration are key processes that occur in response to injury (such as after balloon angioplasty) resulting in intimal thickening. The promoter regions of genes that regulate SMC growth contain recognition elements for the immediate-early gene, early growth response-1 (EGR-1) (18) . EGR-1 is a prototypic member of the zinc ®nger family of transcription factors (19) , and is rapidly upregulated following mechanical injury both *To whom correspondence should be addressed. Tel: +61 2 9385 2537; Fax: +61 2 9385 1389; Email: L.Khachigian@unsw.edu.au in vitro and in vivo and by numerous other agonists such as growth factors, cytokines, hormones and environmental stimuli (20, 21) . We have demonstrated that DNAzymes targeting EGR-1 can serve as useful therapeutic agents in the context of restenosis by their capacity to inhibit intimal thickening in rodent (22, 23) and porcine (24) models.
In the present study we compared LNA-modi®ed DNAzymes targeting EGR-1 with their native phosphodiester counterparts in the context of in vitro substrate cleavage, protein expression, SMC proliferation and regrowth after mechanical injury.
MATERIALS AND METHODS

Oligonucleotides
LNA-modi®ed DNAzymes (LzF4 and LzF4SCR) were synthesized by Proligo France SAS and the unmodi®ed DNAzymes were synthesized by Trilink Biotechnologies (San Diego, USA). The sequences of the DNAzymes (DzF and DzFSCR) and LNA-modi®ed DNAzymes (LzF4 and LzF4SCR) are as follows: 5¢-GCGGGGACAGGCTAG-CTACAACGACAGCTGCAT-(3¢±3¢ T)-3¢, DzF; 5¢-GGAG-CTGACGGCTAGCTACAACGAGATCGACGC-(3¢±3¢ T)-3¢, DzFSCR; 5¢-GCGgGGaCAGGCTAGCTACAACGACAGCtGCaT-(3¢±3¢ T)-3¢, LzF4 and 5¢-GGAgCTgACGGCTAGCTACAACGAGATcGAcGC-(3¢±3¢ T)-3¢, DzFSCR, where capitalized letters represent unmodi®ed monomers and lower case letters represent LNA-modi®ed monomers.
Cell culture and transfection
Primary human aortic SMCs were obtained from American Type Culture Collection (Manassas, VA) and cultured in Waymouth's medium pH 7.4, supplemented with 10% fetal bovine serum (FBS), 10 mg/ml streptomycin and 10 U/ml penicillin at 37°C and 5% CO 2 . Cells were passaged by washing twice in PBS followed by trypsinization. Unless otherwise stated, subcon¯uent SMCs (75%) were growtharrested in serum-free conditions for 6 h before transfecting with DNAzyme or LNA-modi®ed DNAzyme using FuGENE6 (Roche Diagnostics GmbH, Mannheim, Germany). Cells were transfected a second time in the presence of 5% FBS 18 h following the initial transfection.
In vitro transcription and cleavage of RNA substrate A 32 P-labelled, 388-nucleotide EGR-1 RNA transcript was prepared by in vitro transcription (T7 RNA polymerase) of the plasmid construct pBlueScript2 and linearized before transcription with BamHI. Reactions were performed in a ®nal volume of 20 ml containing 10 mM MgCl 2 , 5 mM Tris pH 7.5, 150 mM NaCl, wherein the substrate to DNAzyme or LNAmodi®ed DNAzyme ratios were 1:1, 1:10, 1:20 and 1:50. Reactions proceeded at 37°C for 3 h then were quenched by transfer of aliquots to tubes containing formamide-loading buffer (5) . Samples were denatured at 95°C for 5 min, placed on ice for 1 min and separated on 12% polyacrylamide denaturing gels followed by detection by phosphor imager.
SMC proliferation assay
SMCs were seeded into 96 well plates (3000 cells/well). For comparative studies, subcon¯uent SMCs were transfected with either 20 or 50 nM DNAzyme or LNA-modi®ed DNAzyme. Seventy-two hours following the second transfection, cells were trypsinized and resuspended in 10 ml of isotone solution for counting. Cells were then counted using an automated Coulter counter (Coulter Z Series, Miami, USA).
Western blot analysis
SMCs were cultured in 10 mm tissue culture plates (Falcon, Becton Dickinson, Franklin Lakes, USA) and transfected with 0.2 mM DNAzyme or LNA-modi®ed DNAzyme. One hour following the second transfection in the presence of 5% FBS, cells were washed twice in 1Q PBS and total protein was extracted in 150 mM NaCl, 50 mM Tris±HCl (pH 7.5), 1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 5 mM EDTA, 10 mg/ml leupeptin, 1% aprotinin and 2 mM PMSF. Ten micrograms of protein sample was loaded onto a 10% SDS±PAGE and electroblotted onto a PVDF nylon membrane (Millipore, Bedford, USA). Membranes were blocked in 0.05% Tween 20 (v/v) PBS containing 5% skim milk then incubated with rabbit polyclonal EGR-1 antibodies (Santa Cruz, CA) before being stripped and reprobed with rabbit polyclonal YY1 antibodies (Santa Cruz, CA) at a concentration of 2 mg/ml. Membranes were then incubated with a HRPlinked swine anti-rabbit IgG secondary antibody (Dako, Carpinteria, USA). Protein bands of interest were visualized by chemiluminescent detection (NEN, Boston, USA).
SMC injury/migration assay
SMCs were grown to con¯uence in 8 well chamber slides (Nunc, Copenhagen, Denmark) and transfected with 0.1 mM DNAzyme or LNA-modi®ed DNAzyme. After the second transfection in 5% FBS, injury was performed with a single scratch using a sterile toothpick. Forty-eight hours following injury, cells were ®xed in 5% formaldehyde (v/v), stained with haematoxylin and eosin, and analyzed by light microscopy. Cells in the denuded zone were counted at two different ®elds and expressed as the mean T standard error of the mean (SEM).
RESULTS
LNA-modi®ed DNAzyme cleaves EGR-1 mRNA with greater potency than DNAzyme
Prior to evaluating the effect of LzF4 on cellular activity, we determined the ability of this molecule to cleave its EGR-1 mRNA substrate compared to its all-phosphodiester cleaving counterpart, DzF. Both DzF and LzF4 target the A 301 U junction in human EGR-1 mRNA. The 388 nt 32 P-labelled EGR-1 transcript was produced from a linearized plasmid template using T7 RNA polymerase. DNAzyme cleavage of this substrate is expected to produce 349 and 39 nt fragments; the latter is resolved by 12% denaturing PAGE. Cleavage conditions with RNA:DNAzyme/LNA-modi®ed DNAzyme ratios of 1:1, 1:10, 1:20 and 1:50 demonstrated that LzF4 cleaved with greater potency compared to the unmodi®ed DzF after 3 h (Fig. 1) . LNA incorporation constrains the ribose ring of the LNA-modi®ed nucleotide which, in turn, results in increased binding af®nity (on-rate) for the complementary sequence (14,15).
DNAzyme and LNA-modi®ed DNAzyme inhibition of SMC proliferation
Having shown the capacity of LzF4 to cleave its substrate, we next determined whether it could in¯uence SMC proliferation in the presence of serum (5%), an inducer of EGR-1 gene expression (20) . We demonstrated that DzF and LzF4 both strongly inhibit SMC proliferation at 50 nM (Fig. 2) . LzF4, at this concentration, inhibited serum-inducible SMC proliferation virtually to completion. Back-titrating the concentration of both molecules revealed greater potency by LzF4, which, at 20 nM, produced >50% inhibition whereas DzF was not effective at this concentration (Fig. 2) . In contrast, neither DzFSCR nor LzF4SCR possessed any signi®cant inhibitory effect on serum-inducible SMC proliferation at either concentration. These data demonstrate dose-dependent inhibition by both molecules, but greater cleavage and anti-proliferative activity by LzF4.
LNA-modi®ed DNAzyme and DNAzyme inhibit induction of EGR-1 protein
We transfected growth-quiescent SMC with 0.2 mM of DzF or LzF4 prior to stimulation with serum (5%). Western blot analysis revealed that LzF4 and DzF inhibited EGR-1 protein induction 1 h after exposure to serum, with more potent inhibition by LzF4 (Fig. 3 ). DzFSCR and LzF4SCR had no in¯uence on levels of EGR-1 (Fig. 3) . Reprobing the blot for a second zinc ®nger transcription factor (YY1) demonstrated that neither serum, DzF or LzF4 had any in¯uence over YY1 expression (Fig. 3) .
LNA-modi®ed DNAzymes block SMC regrowth after injury in vitro
Injury by scraping, in¯icted onto a con¯uent monolayer of SMCs triggers a regenerative response which results in complete regrowth from the wound edge into the denuded zone (22) . LzF4 and DzF each inhibited this process, whereas both DzFSCR and LzF4SCR failed to in¯uence this response ( Fig. 4A and B) . In line with our observations with SMC proliferation, EGR-1 protein expression, in vitro RNA cleavage activity and SMC repair, LzF4 was superior to DzF at the same molar concentration.
DISCUSSION
In the present study, we generated LNA-modi®ed DNAzymes targeting the human EGR-1 transcript, where two nucleotides in each of the hybridizing arms were substituted with LNA monomers. This is the ®rst demonstration where a mixed LNA-modi®ed DNAzyme is compared side by side to its unmodi®ed counterpart in a biological setting. Our studies show that the LNA-modi®ed DNAzyme is more superior at cleaving a 388 nt 32 P-labelled EGR-1 transcript, inhibiting endogenous EGR-1 protein expression, SMC proliferation and regrowth from the wound edge after injury. Figure 1 . Cleavage of target RNA by DzF and LzF4. Each was incubated with a 32 P-labelled 388 nt human EGR-1 transcript for 3 h at 37°C at the indicated stoichiometric ratios. Upon termination of the reaction, cleavage products were denatured and resolved by electrophoresis on 12% polyacrylamide denaturing gels. DzFSCR and LzF4SCR were used in parallel at the indicated stoichiometries. Figure 2 . Dose-dependent inhibition of human aortic SMC proliferation by DzF and LzF4 in vitro. Growth-arrested human aortic SMCs were transfected with DNAzymes in 96 well plates and exposed to 5% FBS for 72 h. Numbers of cells in each group were counted using an automated coulter counter. ODN denotes oligonucleotide. * indicates P < 0.001; # indicates P = 0.005 using Student's t-test (two-tailed, unequal variance).
Recent studies have demonstrated that LNA monomers introduced into the substrate recognition arms of DNAzymes resulted in increased cleavage of substrate. Vester et al. (13) showed that a DNAzyme with two T nucleotides in each of its arms replaced with LNA-T monomers greatly increased the cleavage ef®ciency of these molecules, consistent with our ®ndings demonstrating that the LNA-modi®ed DNAzyme (LzF4) was more active than DNAzyme (DzF) under single turnover conditions. LNA-modi®ed DNAzymes cleave their target sequences at signi®cantly higher reaction rates in the presence of excess DNAzyme (9,13). Due to increased binding af®nity of oligonucleotides incorporating LNAs, the number of LNA substitutions in¯uences the enzymatic reaction rate. LNA-modi®ed DNAzymes bearing four LNA substitutions on each of the substrate recognition arms have profoundly reduced reaction rates below those of the unmodi®ed DNAzyme counterpart (9) , whereas the reaction rate of a DNAzyme bearing two LNA substitutions on each of the hybridizing arms does not decelerate reaction rates under multiple turnover conditions (13) .
DNAzymes, to date, have been generated toward a number of key genes that play critical roles in different disease states (22±29). The stability of these agents is an important factor, especially considering their potential use in vivo. Modi®cations such as PS backbones or 3¢±3¢-inverted Ts have been employed to increase stability and nuclease resistance. PS linkages have been widely used to increase stability, however, this modi®cation can display af®nity for various cellular proteins resulting in sequence-independent effects (4,5). A 3¢±3¢-inverted T is now a preferred modi®-cation to increase the half-life of a DNAzyme. We and others have shown that the addition of a 3¢±3¢-inverted T increases the half-life of a DNAzyme from <2 to >22 h (7, 8, 22) . Recent ®ndings indicate that a 3¢±3¢-inverted T does not alter the kinetic behaviour of the enzyme, whereas PS modi®cation may affect cleavage ef®ciency by decreasing cleavage reaction rates to one ®fth that of the unmodi®ed DNAzyme under single turnover conditions and virtually to zero under multiple turnover conditions (9) . Assessment of the intracellular cleavage activity and stability of DNAzymes revealed that a 3¢±3¢-inverted T-modi®ed DNAzyme extracted from transfected cells, was still capable of cleaving its substrate, in vitro (8) . In addition, an LNA±DNA mix-mer is more stable in serum than its all PS-oligonucleotide counterpart (17) .
Studies, prior to the present, have not applied LNAmodi®ed DNAzymes in a biological setting, although antisense LNA oligonucleotides have been used (16,17,30± 32) . LNA-modi®ed oligonucleotides enter living cells ef®-ciently using cationic lipid carriers similar to that used in our study (17, 31) . Comparative studies using PS-and LNA oligonucleotides demonstrate that PS-oligonucleotides cause toxicity (17) and are even capable of stimulating an immune response (32) . Trypan Blue exclusion studies revealed that LNA modi®cation to the DNAzyme bore no adverse toxic effects on cells in culture at 20 nM (data not shown). SMC proliferation assays show that both LzF4 or DzF produce dosedependent, sequence-speci®c inhibition. The disadvantage of LNA-modi®ed DNAzymes is that they are signi®cantly more expensive to synthesize compared to unmodi®ed DNAzymes, presently of the order of at least ®ve times. Although LNA modi®cation increases resistance to nucleolytic degradation, the melting temperature [T m (°C)] of these oligonucleotides is high resulting in slower cleavage reaction rates when compared to their 2¢-O-methyl oligoribonucleotide counterpart, which have lower T m (°C) (9) . Whether LNA-modi®ed DNAzymes become clinically useful remains to be seen.
